Global Primaquine Market Size By Type (Injectables, Capsules), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Primaquine Market was valued at USD 240 million in 2023 and is projected to reach USD 385 million by 2031, growing at a CAGR of 6.1% during the forecast period from 2023 to 2031. Primaquine, an antimalarial medication primarily used to treat and prevent relapse of Plasmodium vivax and Plasmodium ovale infections, continues to see rising demand due to renewed global initiatives targeting malaria elimination and a growing focus on radical cure strategies. Increased awareness and public health investments in endemic regions, especially Asia-Pacific and Africa, are fueling the market expansion.

Drivers:

1. Global Malaria Elimination Efforts:

Significant investments from governments, the WHO, and non-profit organizations are accelerating malaria eradication campaigns. Primaquine, being the only widely used drug effective against dormant liver stages of P. vivax, is central to these eradication strategies.

2. Rise in Plasmodium Vivax Cases:

Despite overall declines in malaria incidence, P. vivax remains prevalent in many regions. Countries in Southeast Asia and South America are observing persistent or resurging P. vivax cases, increasing demand for primaquine therapy.

3. Improved Access Through Public Health Initiatives:

Enhanced supply chain capabilities, bulk procurement through global health bodies, and better availability of generic primaquine are expanding its reach in low-income and malaria-prone regions.

Restraints:

1. Risk of Hemolysis in G6PD-Deficient Individuals:

Primaquine can induce hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This risk necessitates screening before treatment, limiting widespread adoption in resource-limited settings where G6PD testing is not universally available.

2. Limited Commercial Incentives:

Being an older generic drug primarily used in low-income countries, primaquine offers limited profitability, discouraging R&D and newer formulation development by pharmaceutical companies.

Opportunity:

1. Development of Fixed-Dose Combinations:

The advancement of fixed-dose combination therapies with other antimalarials, such as chloroquine or tafenoquine, presents significant commercial potential by improving adherence and treatment outcomes.

2. Expansion of Preventive Use in Military and Traveler Populations:

An increasing number of travelers and military personnel deployed in malaria-endemic areas are receiving primaquine for prophylaxis. This represents a small but growing niche market in non-endemic developed countries.

Market by System Type Insights:

Primaquine is available in two primary dosage forms: tablets and suspension formulations. The tablet segment accounted for the largest market share in 2023 due to its widespread use in adult treatment regimens. However, the suspension segment is expected to grow rapidly, driven by pediatric demand and easier dosing in field settings.

Market by End-use Insights:

The public health programs segment dominated the end-use landscape in 2023, as primaquine is primarily procured by international health agencies and distributed through government programs in endemic regions. Hospital pharmacies and travel clinics also represent growing end-user segments, particularly in developed nations addressing travel-related malaria prevention.

Market by Regional Insights:

Asia-Pacific emerged as the largest regional market in 2023, accounting for over 40% of the global revenue, driven by a high prevalence of P. vivax malaria and robust public health efforts. Africa is anticipated to register the fastest growth rate during the forecast period, supported by increased funding from global malaria initiatives. Meanwhile, Latin America and Middle East regions are steadily increasing primaquine uptake due to national malaria control strategies.

Competitive Scenario:

Key players in the Global Primaquine Market include Sanofi S.A., Ipca Laboratories Ltd., Remedica Ltd., Macleods Pharmaceuticals, Cipla Ltd., Strides Pharma Science Ltd., and GlaxoSmithKline plc. These companies focus on bulk supply agreements with WHO and national governments, formulation development, and expansion into untapped markets. Noteworthy developments include:

2023: Cipla Ltd. received WHO prequalification for its pediatric primaquine formulation, expanding its role in global malaria control programs.

2022: Ipca Laboratories partnered with the Global Fund to scale primaquine access in East Africa through a pooled procurement mechanism.

Scope of Work – Global Primaquine Market

Key Market Developments:

January 2023: WHO updated its malaria treatment guidelines to emphasize broader use of primaquine for relapse prevention in P. vivax malaria.

May 2023: Sanofi expanded its access program to supply affordable primaquine in Sub-Saharan Africa through a partnership with the Medicines for Malaria Venture.

October 2024: Macleods Pharmaceuticals launched a new pediatric-friendly dispersible primaquine tablet in India and Southeast Asia.

FAQs:

1) What is the current market size of the Global Primaquine Market?

The Global Primaquine Market was valued at USD 240 million in 2023.

2) What is the major growth driver of the Global Primaquine Market?

The primary growth driver is the increasing demand for radical cure therapies amid global malaria elimination efforts.

3) Which is the largest region during the forecast period in the Global Primaquine Market?

Asia-Pacific is the largest regional market due to high disease prevalence and active public health interventions.

4) Which segment accounted for the largest market share in Global Primaquine Market?

The tablet segment led the market in 2023, favored for its broad use in adult malaria treatment.

5) Who are the key market players in the Global Primaquine Market?

Key players include Sanofi S.A., Ipca Laboratories, Remedica, Cipla Ltd., and Macleods Pharmaceuticals.